MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.36 CHF | +5.00% |
|
-0.30% | -2.33% |
| Mar. 15 | Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 15 | Molecular Partners Swings to Loss in FY23; Revenue Down | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 377.3 | 604.8 | 575.4 | 200.5 | 113 | 110.4 | - | - |
| Enterprise Value (EV) 1 | 283.5 | 431.1 | 442.6 | -48.67 | 113 | 110.4 | 110.4 | 110.4 |
| P/E ratio | -10.2 x | -8.27 x | -8.65 x | 1.74 x | -1.82 x | -1.98 x | -1.81 x | -1.53 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 18.5 x | 65 x | 59 x | 1.06 x | 16.1 x | 7.97 x | 5.92 x | 6.21 x |
| EV / Revenue | 18.5 x | 65 x | 59 x | 1.06 x | 16.1 x | 7.97 x | 5.92 x | 6.21 x |
| EV / EBITDA | -11 x | -10.9 x | -9.46 x | 1.68 x | -1.93 x | -2.05 x | -2.29 x | -1.66 x |
| EV / FCF | -170 x | -19.9 x | -6.26 x | 1.71 x | -1.9 x | -1.64 x | -1.56 x | -1.3 x |
| FCF Yield | -0.59% | -5.03% | -16% | 58.6% | -52.7% | -60.8% | -64% | -77% |
| Price to Book | 6.99 x | 5.64 x | 5.34 x | 0.85 x | - | 0.98 x | 1.54 x | 6.24 x |
| Nbr of stocks (in thousands) | 21,537 | 29,146 | 32,292 | 32,545 | 32,854 | 32,869 | - | - |
| Reference price 2 | 17.52 | 20.75 | 17.82 | 6.160 | 3.440 | 3.360 | 3.360 | 3.360 |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.4 | 9.3 | 9.754 | 189.6 | 7 | 13.86 | 18.66 | 17.79 |
| EBITDA 1 | -34.19 | -55.44 | -60.85 | 119 | -58.69 | -53.98 | -48.25 | -66.56 |
| EBIT 1 | -37.2 | -58.3 | -63.42 | 116.6 | -61.1 | -63.2 | -70.33 | -84.79 |
| Operating Margin | -182.35% | -626.88% | -650.17% | 61.5% | -872.86% | -455.89% | -376.91% | -476.63% |
| Earnings before Tax (EBT) 1 | -36.8 | -62.8 | -63.78 | 117.8 | -61.98 | -65.7 | -85.7 | -96.3 |
| Net income 1 | -36.8 | -62.8 | -63.78 | 117.8 | -61.98 | -59.74 | -61.79 | -81.01 |
| Net margin | -180.39% | -675.27% | -653.94% | 62.13% | -885.49% | -430.92% | -331.1% | -455.34% |
| EPS 2 | -1.720 | -2.510 | -2.060 | 3.540 | -1.890 | -1.696 | -1.857 | -2.202 |
| Free Cash Flow 1 | -2.22 | -30.43 | -91.89 | 117.4 | -59.58 | -67.2 | -70.7 | -85 |
| FCF margin | -10.88% | -327.25% | -942.03% | 61.91% | -851.14% | -484.75% | -378.87% | -477.79% |
| FCF Conversion (EBITDA) | - | - | - | 98.66% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 99.65% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q3 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.516 | 1.784 | 4.4 | 3.533 | 5.337 | 184.5 | 5.1 | 3.5 | 3.5 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.09 | -35.2 | -34.8 | -12.84 | - | - | - | - | - |
| Operating Margin | -307.24% | -1,973.09% | -790.91% | -363.35% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | -12.31 | - | - | - | - | - |
| Net income 1 | -24.75 | -38.1 | -33.6 | -12.31 | -30.22 | 148.6 | -30.8 | -30.8 | -31.22 |
| Net margin | -329.27% | -2,135.65% | -763.64% | -348.4% | -566.2% | 80.54% | -604.02% | -880% | -891.97% |
| EPS 2 | -1.140 | -1.370 | -1.130 | -0.3800 | -0.9300 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/20 | 2/5/21 | 8/26/21 | 10/28/21 | 3/15/22 | 8/25/22 | 3/9/23 | 8/24/23 | 3/14/24 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 93.8 | 174 | 133 | 249 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.22 | -30.4 | -91.9 | 117 | -59.6 | -67.2 | -70.7 | -85 |
| ROE (net income / shareholders' equity) | -49.8% | -77.9% | -59.5% | 68.8% | -30.1% | -35.3% | -46% | -129% |
| ROA (Net income/ Total Assets) | -27.9% | -42.9% | -35.4% | 54.2% | -26.9% | -31.4% | -39.7% | -97.9% |
| Assets 1 | 131.9 | 146.2 | 180.1 | 217.4 | 230.3 | 190.4 | 155.5 | 82.76 |
| Book Value Per Share 2 | 2.510 | 3.680 | 3.340 | 7.230 | - | 3.430 | 2.180 | 0.5400 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.03 | 1.45 | 0.93 | 1.18 | 0.81 | 5 | 5 | 5 |
| Capex / Sales | 5.05% | 15.6% | 9.57% | 0.62% | 11.54% | 36.07% | 26.79% | 28.11% |
| Announcement Date | 2/6/20 | 2/5/21 | 3/15/22 | 3/9/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.36
CHF
Average target price
9.35
CHF
Spread / Average Target
+178.27%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.33% | 121M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MOLN Stock
- Financials Molecular Partners AG
